Advertisement

Picture Sino Biological Symposium Antibody Engineering Leipzig 650x100px
Document › Details

Poltreg S.A.. (3/11/24). "Press Release: Poltreg’s State-of-the-Art Manufacturing Facility Has Received Approval to Produce Cellular Therapies from the Chief Pharmaceutical Inspectorate in Poland".

Region Region Gdansk (Danzig)
  Country Poland
Organisations Organisation Poltreg S.A.
  Organisation 2 Poland (govt)
Products Product PTG-007 Treg cell therapy (Poltreg)
  Product 2 contract manufacturing (biologicals)
     


PolTREG’s state-of-the-art manufacturing facility has received approval to produce cellular therapies (or Advanced Therapy Medicinal Products) from the Chief Pharmaceutical Inspectorate in Poland.

We can now seek permission to perform clinical trials at the site, including for diseases such as Type-1 Diabetes (T1D) and Multiple Sclerosis with our lead asset PTG-007.

PolTREG has more than 17 years of experience treating patients. We have administered Treg cells to more than 100 people over that period, either in hospital exemption procedures or in clinical trials.


Our state-of-the-art manufacturing facility contains:

15 stand-alone production lines
annual capacity of 1500 therapies
4000 sq. m of space

   
Record changed: 2024-04-19

Advertisement

Picture Sino Biological Symposium Antibody Engineering Leipzig 650x200px

More documents for Poltreg S.A.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px




» top